Bonraybio announced its 2025 fiscal results on March 3, reporting record-breaking performance. Annual revenue reached NT$306 million (+37% YoY), with net profit exceeding NT$100 million and a net margin of 33%, resulting in an EPS of $4.13.

In celebration of its 10th anniversary, Chairman and GM Chen-Teng Hsu announced a strategic rebranding toward "AI-Powered Fertility Science." The company is expanding from its dominant position in male infertility—driven by its "AI Automated Sperm Quality Analyzer"—into the female reproductive market.

Bioteque plans to debut its self-developed oocyte (egg) vitrification and thawing solution at the ESHRE annual meeting in London this July. This new product line aims to minimize egg loss during cryopreservation and is expected to become a major revenue driver. The board has proposed a total dividend of NT$3.75 per share.

Resource: 邦睿去年EPS 4.13元創新高 轉型AI智慧生殖科學